RET and neoplasm: In the present study, the prevalence of BRAFV600E, RAS, TERT promoter mutation, and RET/PTC rearrangement in PTC samples with tumor size ≤15 mm was 84.5% (332/393), 1.0% (4/393), 0.3% (1/393), and 2.8% (11/393), respectively; however, in PTMC samples, no TERT promoter mutation was detected, and the prevalence of BRAFV600E, RAS mutation, and RET/PTC rearrangement was 82.8% (265/320), 0.9% (3/320), and 2.5% (8/320), respectively.